Despite this, the potential protective effect of VEGF inhibitors and HER2 inhibitors against AS progression may have biological plausibility given that they could decrease neoangiogenesis and collagen I overexpression (the most common type of collagen in the aortic valve) (22–25) which play a role in the pathogenesis of AS. The gene discussed is ERBB2; the disease is aortic stenosis.